IVF · INVO Fertility, Inc.
$0.60
+0.00 (+0.10%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.51M
Shares
2.51M
Volume · Oct 20
68.71K
Avg daily vol (3M)
2.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.60
Open$0.61
Day$0.60–0.64
52W close$0.56–27.24
Avg vol 30d135K
Short int50K · 2.0% float · 1.0d
Short vol30%
Last earningsAug 17, 2026
DataNov 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Nov 30, 2026
Est · unconfirmed
· in 6 wks
filed Aug 14, 2026
call held Aug 17, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.53M
Trailing 12 months
Net income (TTM)
−$6.95M
Trailing 12 months
Revenue growth YoY
+16.7%
Year over year
Operating margin
-78.7%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 602,411.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25,987.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.0%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 17, 2026
Q2 FY26
TL;DR. INVO Fertility reported 17% Q2 revenue growth to $2.2M and a profitable clinic platform with ~$333K clinic-level adjusted EBITDA, while the consolidated company posted a $1.0M adjusted EBITDA loss, used $3.7M in cash, and entered a $15M equity purchase facility to fund further acquisitions.
Bullish
- + Q2 revenue grew 17% year-over-year to $2.18M, driven by Family Beginnings and organic growth.
- + Clinic platform remained profitable with clinic-level adjusted EBITDA of ~$333K in Q2, up from ~$164K in Q1.
- + Balance sheet improved, with cash rising to $3.7M and total liabilities falling to ~$9.3M from ~$13M.
- + Company obtained a $15M equity purchase facility with Alumni Capital, expanding financial flexibility for acquisitions and growth.
Bearish
- − Consolidated adjusted EBITDA worsened to ~$(1.0)M from ~$(0.6)M, as public-company and corporate costs outpace clinic earnings.
- − Consolidated loss from operations of ~$1.3M persisted in the quarter despite the year-over-year improvement.
- − Q2 net income of $0.9M was driven primarily by a ~$2.5M non-cash gain on the Birmingham remeasurement, not recurring operations.
- − Net cash used in operations was ~$3M in the first half of 2026, indicating continued cash burn.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−75%
below
Price vs 50-day avg
−35%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−69%
trailing
YTD return
−84%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 9 funds reported for Sep 30 · net +45.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.00% of float · ▼ -74.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
7%
contracting
EPS growth
+94%
Y/Y
Free cash flow
$-7.1M
Quant / Vol
risk profile
Volatility
254%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
12.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−75%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 9 funds reported for Sep 30 · net +45.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.00% of float · ▼ -74.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $27
vs 200-day avg -75%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$1M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) from continuing operations $888,740
+$177,227 Interest expense
-$139,514 Interest income
+$56,154 Tax expense
+$145,573 Depreciation and amortization
+$118,571 Stock-based compensation
+$0 Non cash compensation for services
-$2,452,032 Gain on remeasurement
+$0 Gain on change in fair value of warrant liability
+$172,621 Loss from debt extinguishment
+$0 Gain on settlement of liability
+$0 Impairment of intangible assets
+$0 NAYA divesture related costs
= Adjusted EBITDA -$1,032,660
|
|||
| Clinic-Level Adjusted EBITDA non-GAAP | $333K | Q2 2026 | — |
| Fertility Clinic Services Segment EBITDA non-GAAP | $333,026 | Q2 2026 | — |
| Shares of common stock outstanding | 2,506,969 | As of August 14, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IVF
this stock
INVO Fertility, Inc.
|
$1.51M | — | +4.7% | — | 2.0% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$118.67B | -1.5% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IVF | -6.0% | -39.8% | -68.7% | -33.9% | -84.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -4.8% | -39.3% | -76.8% | -34.7% | -96.8% |